Adaptive immunity programs in breast cancer Adaptive immunity in breast cancer
暂无分享,去创建一个
[1] J. Balko,et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.
[2] Lajos Pusztai,et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Marmé,et al. Immunotherapy in Breast Cancer , 2016, Oncology Research and Treatment.
[4] Chao Cheng,et al. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles , 2016, Nature Communications.
[5] Ash A. Alizadeh,et al. Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .
[6] M. Postow,et al. Immune checkpoint modulation: rational design of combination strategies. , 2015, Pharmacology & therapeutics.
[7] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[8] Chao Cheng,et al. Integrative analysis of survival-associated gene sets in breast cancer , 2015, BMC Medical Genomics.
[9] C. Sentman,et al. Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.
[10] A. Thakur,et al. Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial , 2015, Clinical Cancer Research.
[11] E. Mittendorf,et al. Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer , 2015, BioDrugs.
[12] M. Aglietta,et al. Recent advances in the development of breast cancer vaccines , 2014, Breast cancer.
[13] D. Rimm,et al. Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Clinical Cancer Research.
[14] L. Zitvogel,et al. Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.
[15] Kathleen A Cronin,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. , 2014, Journal of the National Cancer Institute.
[16] Scott D. Brown,et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.
[17] P. Darcy,et al. Clinical application of genetically modified T cells in cancer therapy , 2014, Clinical & translational immunology.
[18] F. Schuetz,et al. Adoptive immunotherapy of metastatic breast cancer: present and future , 2014, Cancer and Metastasis Reviews.
[19] L. Coussens,et al. Dendritic Cells, Inflammation, and Breast Cancer , 2013, Cancer journal.
[20] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[21] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[22] Benjamin Haibe-Kains,et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. , 2013, The Journal of clinical investigation.
[23] A. Schneeweiss,et al. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial , 2013, Cancer Immunology, Immunotherapy.
[24] Stefan Michiels,et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Criscitiello. Tumor-Associated Antigens in Breast Cancer , 2012, Breast Care.
[26] Stefan Michiels,et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] I. Ellis,et al. The prognostic significance of B lymphocytes in invasive carcinoma of the breast , 2012, Breast Cancer Research and Treatment.
[28] S. Leung,et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.
[29] Michael J. Bevan,et al. CD8+ T Cells: Foot Soldiers of the Immune System , 2011, Immunity.
[30] D. Yin,et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.
[31] Ian O Ellis,et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Wei Zheng,et al. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. , 2011, The Lancet. Oncology.
[33] C. Aspord,et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation , 2011, The Journal of experimental medicine.
[34] L. Sherman,et al. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.
[35] Yuan Qi,et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Watanabe,et al. Regulatory T cells and breast cancer: implications for immunopathogenesis , 2010, Cancer and Metastasis Reviews.
[37] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[38] C. Caldas,et al. Triple negative breast cancers: clinical and prognostic implications. , 2009, European journal of cancer.
[39] Achim Rody,et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.
[40] J. Blay,et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.
[41] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[42] H. Kölbl,et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.
[43] B. Chauffert,et al. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.
[44] S. Dermime,et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.
[45] J. A. Lopez,et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer , 2007, British Journal of Cancer.
[46] M. Bregni,et al. Current role of allogeneic stem cell transplantation in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] A. Rosenberg,et al. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.
[48] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[49] Alexander H Enk,et al. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. , 2007, Journal of dermatological science.
[50] C. Aspord,et al. Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development , 2007, The Journal of experimental medicine.
[51] K. Tanabe,et al. Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.
[52] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Beyer,et al. Regulatory T cells in cancer. , 2006, Blood.
[54] C. Schmidt,et al. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction , 2006, Breast Cancer Research.
[55] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[56] M. Sheaff,et al. The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators. , 2003, Surgery.
[57] A. Vincent-Salomon,et al. Tumor Antigens and Antigen-Presenting Capacity in Breast Cancer , 2003, Pathobiology.
[58] D. Hart,et al. Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression , 2002, British Journal of Cancer.
[59] L. Harris,et al. First-Line Herceptin® Monotherapy in Metastatic Breast Cancer , 2001, Oncology.
[60] G. Freeman,et al. CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.
[61] D. Jäger,et al. Challenges to the development of antigen-specific breast cancer vaccines , 2001, Breast Cancer Research.
[62] G. Heppner,et al. Immunological enhancement of breast cancer , 1997, Parasitology.
[63] D. Carbone,et al. Decreased antigen presentation by dendritic cells in patients with breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[64] M. Papamichail,et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer , 1994, Cancer.
[65] J. Hurlimann,et al. Mononuclear cells infiltrating human mammary carcinomas: Immunohistochemical analysis with monoclonal antibodies , 1985, International journal of cancer.
[66] P. Beverley,et al. Characterisation of breast cancer infiltrates using monoclonal antibodies to human leucocyte antigens. , 1984, British Journal of Cancer.
[67] C. Desmarais,et al. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. , 1983, Journal of the National Cancer Institute.
[68] H. Soliman. Immunotherapy strategies in the treatment of breast cancer. , 2013, Cancer control : journal of the Moffitt Cancer Center.
[69] B. Chauffert,et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy , 2010, Breast Cancer Research and Treatment.
[70] F. Quismorio,et al. Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis , 2005, Breast Cancer Research and Treatment.
[71] S. Pillai,et al. Innate immunity. , 1996, Current opinion in immunology.